COMMUNIQUÉS West-GlobeNewswire

OSE Immunotherapeutics met à jour l’information sur les procédures en cours
02/07/2025
OSE Immunotherapeutics met à jour l’information sur les procédures en cours NANTES, France, 2 juillet 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) annonce qu’à la suite de l’audience du [...]
OSE Immunotherapeutics met à jour l’information sur les procédures en cours
02/07/2025
OSE Immunotherapeutics provides an update on ongoing proceedings NANTES, France, July 2, 2025, 8 AM – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that following the hearing on June 24th, 2025, [...]
GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch
02/07/2025
GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch Comprehensive clinical performance study encompassed 646 participant visits, including both Type 2 diabetic [...]
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
02/07/2025
- 500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a [...]
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
02/07/2025
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical [...]
BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate
02/07/2025
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, July 02, 2025 (GLOBE NEWSWIRE) -- The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to jointly develop [...]
Granting of Stock Options and Vesting of Restricted Share Units
02/07/2025
In accordance with the Remuneration Policy of Alvotech (the “Company”), which was approved at the Company’s Annual General Meeting (“AGM”) on June 6, 2023, at the 2025 AGM held on June 25, 2025, four independent board [...]
CapsoVision Announces Pricing of Initial Public Offering
02/07/2025
SARATOGA, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are [...]
Effective Testosterone Booster for Men Over 50: TestoPrime Medically Accredited as the Best Testosterone Supplement for Males In 40's and 50's
01/07/2025
Clinicians’ Choice Testosterone Booster: Medically Reviewed and Endorsed by Leading Experts, Now Available Nationwide Without Prescription New York City, NY, July 01, 2025 (GLOBE NEWSWIRE) -- For men in their 40s and [...]
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01/07/2025
CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of June 26, 2025, [...]
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer
01/07/2025
MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment [...]
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/07/2025
ORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly- [...]
Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies
01/07/2025
ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC 12-month landmark survival of 88% and mOS of 32 months BOSTON, July 01, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/07/2025
CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly- [...]
Venus Concept Announces $6.5 Million Debt-to-Equity Exchange Transaction
01/07/2025
Further reduction of outstanding debt by Madryn Asset Management improves the Company’s balance sheet position TORONTO, July 01, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: [...]
Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025
01/07/2025
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, [...]
ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
01/07/2025
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical [...]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/07/2025
CHARLESTOWN, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/07/2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare [...]

Pages